Available datapackage for study 'Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes'
收藏DataCite Commons2026-03-08 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/dataPackages/PR00012071.0
下载链接
链接失效反馈官方服务：
资源简介：
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin
提供机构：
Vivli
创建时间：
2026-03-08
